Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth.

Journal of cancer research and clinical oncology - 1 Apr 2021

Bai Chenguang, Xu Yi, Qiu Cen

Abstract excerpt

PURPOSE: Imatinib, a small-molecule tyrosine kinase inhibitor, has shown good clinical activity by inhibiting adenosine triphosphate (ATP) binding to the receptor. Unfortunately, majority of patients eventually develop drug resistance, which limits the long-term benefits of the tyrosine kinase inhibitors and poses a significant challenge in the clinical management of GIST. The aim of our study was to explore the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Apoptosis
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Gene Expression Regulation, Neoplastic

Share to Protein Multimerization

Share to Proto-Oncogene Proteins c-kit

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 33389076
DOI: 10.1007/s00432-020-03490-6
PMCID: PMC7954730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth.PMID 33389076Read ↗

A New Monoclonal Antibody that Blocks KIT Dimerisation and Inhibits Gastrointestinal Stromal Tumour GrowthSemantic proximity Read ↗

KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.Semantic proximity Read ↗

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.Semantic proximity Read ↗

Targeting the translational machinery in gastrointestinal stromal tumors (GIST) – a new therapeutic vulnerabilitySemantic proximity Read ↗

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Semantic proximity Read ↗

Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.Semantic proximity Read ↗

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.Semantic proximity Read ↗

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.Semantic proximity Read ↗

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.Semantic proximity Read ↗

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.Semantic proximity Read ↗

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.Semantic proximity Read ↗

Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.